CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 113 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $37,583,389 | +7.1% | 1,263,732 | -35.1% | 1.25% | +23.5% |
Q2 2023 | $35,083,805 | -38.5% | 1,946,937 | -45.2% | 1.02% | -39.8% |
Q1 2023 | $57,091,485 | -22.8% | 3,554,887 | -12.0% | 1.69% | -18.8% |
Q4 2022 | $73,918,751 | -29.3% | 4,039,276 | -24.1% | 2.08% | -31.6% |
Q3 2022 | $104,505,000 | +5.3% | 5,321,032 | 0.0% | 3.03% | -2.4% |
Q2 2022 | $99,237,000 | -12.4% | 5,321,032 | +3.1% | 3.11% | +36.9% |
Q1 2022 | $113,339,000 | -61.4% | 5,163,517 | -50.0% | 2.27% | +0.3% |
Q4 2021 | $293,392,000 | +251.7% | 10,327,034 | +160.6% | 2.26% | +86.7% |
Q3 2021 | $83,432,000 | -44.2% | 3,963,517 | -50.0% | 1.21% | +24.9% |
Q2 2021 | $149,424,000 | +189.5% | 7,927,034 | +116.6% | 0.97% | +48.5% |
Q1 2021 | $51,606,000 | -0.1% | 3,659,381 | 0.0% | 0.65% | +17.9% |
Q4 2020 | $51,634,000 | -10.0% | 3,659,381 | 0.0% | 0.55% | -33.8% |
Q3 2020 | $57,342,000 | -3.1% | 3,659,381 | 0.0% | 0.84% | -12.7% |
Q2 2020 | $59,171,000 | +55.5% | 3,659,381 | +41.4% | 0.96% | -3.2% |
Q1 2020 | $38,042,000 | -41.4% | 2,587,953 | 0.0% | 0.99% | -23.2% |
Q4 2019 | $64,931,000 | +66.8% | 2,587,953 | 0.0% | 1.29% | +23.0% |
Q3 2019 | $38,922,000 | -39.8% | 2,587,953 | 0.0% | 1.05% | -29.4% |
Q2 2019 | $64,698,000 | +9.8% | 2,587,953 | 0.0% | 1.48% | -10.6% |
Q1 2019 | $58,901,000 | -24.1% | 2,587,953 | 0.0% | 1.66% | -43.7% |
Q4 2018 | $77,612,000 | +4.7% | 2,587,953 | 0.0% | 2.95% | +49.0% |
Q3 2018 | $74,144,000 | – | 2,587,953 | – | 1.98% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |